Supramolecular peptide hydrogel epitope vaccine functionalized with CAR-T cells for the treatment of solid tumors.

ABSTRACT: Chimeric antigen receptor T-cell (CAR-T) therapy, which benefits from the perfect combination of gene editing techniques and antibody engineering, has shown outstanding clinical efficacy in hematological malignancies. Solid tumors present the next challenge due to their extremely complicated microenvironment and structural characteristics. Targeting efficiency and persistence are currently bottleneck issues in the clinical treatment of CAR-T. Beyond drugs and cytokines, biomaterials can modulate the immune response, assisting adoptive CAR-T cells in exerting their function. In this study, a supramolecular peptide hydrogel epitope vaccine was designed to serve as both a preparation medium and a reservoir for CAR-T cells. The self-assembling peptide formed a nanofiber scaffold through non-co

SUBMITTER: Yang P 

PROVIDER: S-EPMC11804731 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature